| Species |
Human |
| Protein Construction |
HLA-A*02:01&B2M&HPV 16 E6 (KLPQLCTEL) Monomer [Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and KLPQLCTEL peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&KLPQLCTEL |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
50.50 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 53-63 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Human papillomavirus (HPV) 16 infection is a necessary condition for the pathogenesis and development of cervical cancer. The E6 protein is expressed by the HPV16 E6 gene and promotes malignant phenotype transformation, which is an important mechanism for the occurrence and development of cervical cancer. |
| Synonyms |
Human papillomavirus type 16; HPV16; E6 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
